Literature DB >> 2416014

Galanin potentiates electrical stimulation and exogenous norepinephrine-induced contractions in the rat vas deferens.

T Ohhashi, D M Jacobowitz.   

Abstract

In order to evaluate the mode of action of galanin (GAL) on the neuroeffector mechanism of peripheral sympathetic nerve fibers, the effects of this peptide were tested on the electrical stimulated and the unstimulated preparations of the isolated rat vas deferens in the presence of 10(-7) M atropine. The contractile responses, which were mediated predominantly by activation of postganglionic noradrenergic nerve fibers were dose-dependently potentiated by GAL in concentrations ranging from 1 to 50 nM. The facilitatory action induced by GAL in high concentrations (greater than 10 nM) usually returned to the control level at 2-3 min and were tachyphylactic. The potentiating action of GAL was not modified by pretreatment with 10(-7) M propranolol. Contractions produced by exogenous norepinephrine (NE) in the unstimulated preparations were not affected by pretreatment with low concentrations (less than 5 nM) of GAL. On the other hand, the contractions were dose-dependently potentiated 1 min after pretreatment with higher concentrations (greater than 10 nM) of GAL, which recovered 15 min after constant flow washout. Contractions developed by exogenous 5-hydroxytryptamine were not affected, or slightly inhibited, by GAL (1-50 nM). In some preparations without electrical stimulation, high concentrations of GAL caused a slight contraction, which was not blocked by pretreatment with 10(-6) M phentolamine and 10(-6) M tetrodotoxin. These results suggest that GAL receptors exist presynaptically in the rat vas deferens and that stimulation of the receptors by GAL potentiates the release of NE from the nerve terminals during postganglionic sympathetic nerve stimulation. Other mechanisms for GAL action, such as influence on neuronal uptake and catecholamine metabolism, cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416014     DOI: 10.1016/0167-0115(85)90197-1

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

Review 1.  Galanin.

Authors:  M E Vrontakis; A Torsello; H G Friesen
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

2.  Galanin-immunoreactive nerves in the rat iris: alterations induced by denervations.

Authors:  I Strömberg; H Björklund; T Melander; A Rökaeus; T Hökfelt; L Olson
Journal:  Cell Tissue Res       Date:  1987-11       Impact factor: 5.249

3.  Galanin-immunoreactive nerves in the female rat paracervical ganglion and uterine cervix: distribution and reaction to capsaicin.

Authors:  R E Papka; H H Traurig
Journal:  Cell Tissue Res       Date:  1989-07       Impact factor: 5.249

4.  NPY-, galanin-, VIP/PHI-, CGRP- and substance P-immunoreactive neuronal subpopulations in cat autonomic and sensory ganglia and their projections.

Authors:  B Lindh; J M Lundberg; T Hökfelt
Journal:  Cell Tissue Res       Date:  1989       Impact factor: 5.249

5.  Prolonged inhibition of cardiac vagal action following sympathetic stimulation and galanin in anaesthetized cats.

Authors:  M Revington; E K Potter; D I McCloskey
Journal:  J Physiol       Date:  1990-12       Impact factor: 5.182

6.  Effects of galanin, its analogues and fragments on rat isolated fundus strips.

Authors:  S Katsoulis; W E Schmidt; H Schwörer; W Creutzfeldt
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

7.  Galanin-like immunoreactivity in extrinsic and intrinsic nerves to the gut of the Atlantic cod, Gadus morhua, and the effect of galanin on the smooth muscle of the gut.

Authors:  P Karila; A C Jönsson; J Jensen; S Holmgren
Journal:  Cell Tissue Res       Date:  1993-03       Impact factor: 5.249

8.  Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.

Authors:  U Kahl; U Langel; T Bartfai; L Grundemar
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.